Brief: Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202
28/05/2025 14:25
May 28 (Reuters) - Quantum BioPharma Ltd QNTM.CD: QUANTUM BIOPHARMA RECEIVES ETHICS COMMITTEE APPROVAL FOR PHASE 2 CLINICAL TRIAL OF FSD202 FOR NOCIPLASTIC PAIN IN PATIENTS WITH IDIOPATHIC MAST CELL ACTIVATION SYNDROME Source text: ID:nGNXbLz0WK Further company coverage: QNTM.CD ((Reuters.Briefs@thomsonreuters.com;))